Child-safety cap issue leads to potassium tablet recall
Aspen Pharmacare, in consultation with the TGA, has initiated a recall of Span-K (potassium chloride) 600 mg tablets.
The recall has been initiated for product correction after it was identified that bottles of this medicine have been supplied without child-resistant caps.
The manufacturer says there is no concern regarding the quality or safety of these medicines, other than the absence of the child-resistant packaging.
To correct the issue, Aspen Australia has initiated a recall to replace all caps on bottles of Span-K 600 mg tablets, irrespective of batch number or expiry date.
Aspen Pharmacare says it has written to hospital and retail pharmacies providing further information about this issue.
Additionally, the sponsor has provided affected pharmacies a supply of suitable child resistant caps to be used in this recall for product correction at the point of dispensing.
“If you are treating a patient who is taking Span-K 600 mg tablets, advise them of this issue,” the company says.
“Instruct them to return their medicine to a pharmacy so that the cap can be replaced with one that is child-resistant”.
“Reassure patients that there is no other concern regarding the quality or safety of these medicines, but consider reminding them of the importance of keeping all medicine out of the reach of children”.
Span-K 600 mg tablets are used to provide extra potassium for people who have lost potassium from their bodies because of illness or treatment with certain medicines. Span-K is also used for people who do not have enough potassium in their regular diet or cannot replace the potassium they have lost from their diet alone.
Click here for more information
If you have any questions or concerns about this issue, contact Aspen Pharmacare on 1300 659 646